Therapeutics News and Research

RSS

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit.

29 Apr 2015

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer.

29 Apr 2015

Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its TransCon technology to address significant unmet medical needs, announced today that its Phase 1 single ascending dose study of TransCon Treprostinil produced dose-dependent increases in plasma treprostinil levels in-line with expectations.

29 Apr 2015

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a $5.5 billion Company valuation. Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies.

28 Apr 2015

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark.

27 Apr 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.

From Baxter International Inc. 27 Apr 2015

aTyr's Resolaris granted FDA Orphan Drug Designation for treatment of FSHD

aTyr Pharma, a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today that Resolaris has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

27 Apr 2015

New study shows significant influence of daily drinking on cirrhosis

According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver Congress 2015 has shown the significant influence of daily drinking on this disease burden.

25 Apr 2015

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Ahmad M. Khalil, PhD, knew the odds were against him -- as in thousands upon thousands to one. Yet he and his team never wavered from their quest to identify the parts of the body responsible for revving up one of the most aggressive forms of breast cancer, HER2+. This month in Breast Cancer Research and Treatment, Khalil and his colleagues at Case Western Reserve University proved the power of persistence; from a pool of more than 30,000 possibilities, they found 38 genes and molecules that most likely trigger HER2+ cancer cells to spread.

25 Apr 2015

Oncologists publish review of advanced clinical treatments for pancreatic cancer

The oncologists Manuel Hidalgo, Director of the Clinical Research Programme of the Spanish National Cancer Research Centre, and Ignacio Garrido-Laguna, member of the Experimental Therapeutics Program at Huntsman Cancer Institute of the University of Utah (USA), have recently published a review of state-of-the-art clinical treatments for pancreatic cancer -- including the most current therapies and innovative research -- in the prestigious scientific journal Nature Reviews Clinical Oncology.

24 Apr 2015

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia.

24 Apr 2015

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service (DATIS) based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia.

24 Apr 2015

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

24 Apr 2015

Several drugs could lead to new MS treatment options

New research published this week in Nature has found several drugs could lead to new treatment options for multiple sclerosis (MS), including two drugs that effectively treat MS at the source, in vivo. When administered at the peak of disease, these two drugs showed a striking reversal of disease severity.

23 Apr 2015

ADCs based on alpha-amanatin may help treat colorectal cancer

For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

23 Apr 2015

ATA guidelines provide recommendations for managing thyroid nodules and thyroid cancer in children

Previous guidelines from the American Thyroid Association for evaluating and managing thyroid nodules and thyroid cancers targeted adults. Recognizing the potential differences in clinical presentation and long-term outcomes, and the potential risks of overly aggressive therapy in pediatric patients with thyroid cancer, an ATA Task Force developed management guidelines for children with thyroid nodules and differentiated thyroid cancer (DTC), which are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers and the official journal of the American Thyroid Association.

23 Apr 2015

Survivors of Ebola epidemic donate plasma to tackle disease outbreaks in West Africa

The first donations of plasma, from survivors of the Ebola epidemic in Sierra Leone, have been received by an international research team working to help tackle current and future disease outbreaks in West Africa.

23 Apr 2015

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration.

22 Apr 2015

Therapeutics News and Research

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

aTyr's Resolaris granted FDA Orphan Drug Designation for treatment of FSHD

New study shows significant influence of daily drinking on cirrhosis

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Oncologists publish review of advanced clinical treatments for pancreatic cancer

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Several drugs could lead to new MS treatment options

ADCs based on alpha-amanatin may help treat colorectal cancer

ATA guidelines provide recommendations for managing thyroid nodules and thyroid cancer in children

Survivors of Ebola epidemic donate plasma to tackle disease outbreaks in West Africa

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Advancing therapeutic biopolymer development eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News